drugset
drugset / Trial / NCT00838578

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

NCT00838578 ↗

Phase 1/2 Terminated 65 enrolled Kyowa Kirin, Inc. Kyowa Hakko Kirin Pharma, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the Phase II portion of this study is to assess the efficacy of KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)/CapOx (capecitabine and oxaliplatin) treatment failure in patients with metastatic colorectal cancer.

Timeline

Start
2009-03
Primary completion
2012-07
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 180 mg/m2 —
Subject KRN330 Monoclonal antibody 0.5 mg/kg —

Indications

colorectal cancer